A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors
The goal of this study is to evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of YZJ-5053 Tablets in Participants with Advanced Solid Tumors
Solid Tumor
DRUG: YZJ-5053 tablets
Determination of Maximum Tolerated Dose (MTD) of YZJ-5053, The MTD will be based on dose limiting toxicity (DLT), 21days as a cycle|To identify a recommended Phase 2 dose (RP2D) of YZJ-5053, RP2D will be be based on MTD, 21days as a cycle|Number of participants with treatment-related adverse events as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0), All events with a Grade 3 or above toxicity (defined by the NCI-CTCAE 5.0) will be tabulated by event and by relationship to YZJ-5053, 21days as a cycle
Maximum observed plasma concentration (Cmax) of YZJ-5053, Maximum plasma concentration of YZJ-5053 after single and multiple dose administration of YZJ-5053, single dose: predose, 0.5、1、2、4、6、8、12、24、48、72 hours post-dose. multiple dose: predose on days 1、3、4、5、6, and 0.5、1、2、4、6、8、12 hours post-dose on day 5|Time to reach Cmax (Tmax) of YZJ-5053, The amount of time to reach Cmax after single and multiple dose administration of YZJ-5053, single dose: predose, 0.5、1、2、4、6、8、12、24、48、72 hours post-dose. multiple dose: predose on days 1、3、4、5、6, and 0.5、1、2、4、6、8、12 hours post-dose on day 5|Terminal half-life (t1/2) of YZJ-5053, Terminal half-life (t1/2) after single and multiple dose administration of YZJ-5053, single dose: predose, 0.5、1、2、4、6、8、12、24、48、72 hours post-dose. multiple dose: predose on days 1、3、4、5、6, and 0.5、1、2、4、6、8、12 hours post-dose on day 5|Area under the plasma concentration-time curve (AUC) of YZJ-5053, Area under the plasma concentration versus time curve after single and multiple dose administration of YZJ-5053, single dose: predose, 0.5、1、2、4、6、8、12、24、48、72 hours post-dose. multiple dose: predose on days 1、3、4、5、6, and 0.5、1、2、4、6、8、12 hours post-dose on day 5|apparent clearance following oral administration for YZJ-5053, To characterise the pharmacokinetics (PK) after single and multiple dose administration of YZJ-5053, single dose: predose, 0.5、1、2、4、6、8、12、24、48、72 hours post-dose. multiple dose: predose on days 1、3、4、5、6, and 0.5、1、2、4、6、8、12 hours post-dose on day 5|apparent volume of distribution for YZJ-5053, To characterise the PK after single and multiple dose administration of YZJ-5053, single dose: predose, 0.5、1、2、4、6、8、12、24、48、72 hours post-dose. multiple dose: predose on days 1、3、4、5、6, and 0.5、1、2、4、6、8、12 hours post-dose on day 5|Objective Response Rate (ORR) as defined by Investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, For solid tumors, this will be determined per RECIST v1.1 guidelines, Evaluate every 6 weeks (±1 week) until study completion, an average of 1 year|Disease control rate (DCR) as defined by Investigator-assessed RECIST v1.1, For solid tumors, this will be determined per RECIST v1.1 guidelines, Evaluate every 6 weeks (±1 week) until study completion, an average of 1 year|Duration Of Response (DOR) as defined by Investigator-assessed RECIST v1.1, For solid tumors, this will be determined per RECIST v1.1 guidelines, Evaluate every 6 weeks (±1 week) until study completion, an average of 1 year|Progression-free Survival (PFS) as defined by Investigator-assessed RECIST v1.1, For solid tumors, this will be determined per RECIST v1.1 guidelines, Evaluate every 6 weeks (±1 week) until study completion, an average of 1 year
Part1(phase 1a) :To define the maximum tolerated dose (MTD) and/or a recommended phase 2 dose(RP2D). To evaluate the safety and tolerability of YZJ-5053 tables in participants with advanced solid tumors.

Part2(phase 1b) : To define the RP2D. To evaluate the safety and tolerability of YZJ-5053 tables in subjects with advanced solid tumors